• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Capecitabine maintenance therapy for metastatic nasopharyngeal carcinoma improves progression-free survival

byKassandra McFarlaneandSamuel Chan
February 28, 2022
in Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Progression-free survival is longer in those treated with capecitabine maintenance therapy as compared with best supportive care

2. Adverse effects experienced by patients in the treatment group were as expected including myelosuppression, hand-foot syndrome and mucositis.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Survival outcomes are improved with the use of capecitabine maintenance therapy, but there has been limited research in the context of metastatic nasopharyngeal carcinoma (NPC). This study aimed to compare capecitabine maintenance therapy versus best supportive care (BSC) on outcomes of progression-free survival (PFS), overall survival (OS), and safety. Disease progression occurred in 23 of 52 patients in the treatment group, compared with 37 of 52 patients in the BSC group. Median PFS in the treatment group was greater than in the BSC group (35.9 months compared to 8.2 months in the BSC group. In the capecitabine group, median OS was not reached, whereas it was 41.5 months in the BSC group. Analysis revealed no significant difference between the groups, however, once patients who received crossover treatment were accounted for, there was a significant OS difference noted in favour of the treatment group. Fifty patients in the capecitabine group experienced adverse effects (AEs) as compared to 48 in the BSC group. The most common mild AEs included anemia, neutropenia, nausea/vomiting, mucositis and hand-foot syndrome. Severe AEs were infrequent, but were noted in the treatment group, including anemia (12%), hand-foot syndrome (10%), nausea/vomiting (6%), among others. Limitations to this study include that the OS results were immature, the sample size was small, it was an open-label design and was a single-centre study. Additionally, patients who were older than 65 years old were excluded from this trial, so the results of this study may not be applicable to an older patient population. Overall, capecitabine can offer improved survival benefits by increased progression-free survival, as well as potentially improved overall survival.

Click to read the study in JAMA Oncology

Relevant Reading: Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety

In-Depth [randomized controlled trial]: This single-centre, open-label, randomized phase 3 clinical trial enrolled and randomly assigned 104 adult patients between the ages of 18 and 65 in a 1:1 fashion to receive either capecitabine maintenance therapy or BSC (52 for each group). Patients were induced with 4-6 cycles of paclitaxel, cisplatin, and ca The primary study outcome was progression-free survival (PFS). Secondary outcomes included overall survival (OS) and safety. Median PFS was 35.9 months (95% confidence interval (CI), 20.5 months – not reached) in the treatment group versus 8.2 months (95% CI, 6.4-10.0 months) in the BSC group. The hazard ratio (HR) was 0.44 (95% CI, 0.26-0.74). Median OS was not reached in the therapy group and was 41.5 months in the BSC group. There were no differences in OS between the two groups [HR, 0.59 (95% CI, 0.30-1.16)]. However, once crossover patients were accounted for, there was a significant OS difference detected in favour of capecitabine [HR, 0.50 (95% CI, 0.26-0.99)]. Adverse events were noted in 50 of 52 patients in the capecitabine group, as compared to 48 of 52 in the BSC group. Anemia, neutropenia, nausea/vomiting, mucositis and hand-foot syndrome were the most common mild AEs. Less common were severe AEs, which included anemia (12%), hand-foot syndrome (10%), nausea/vomiting (6%), among others, within the capecitabine group. Only one person from the treatment group withdrew for serious AEs (nausea/vomiting, fatigue) and no deaths related to the treatment were reported.

RELATED REPORTS

#VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

#VisualAbstract: Upper neck irradiation is noninferior to whole neck irradiation for newly diagnosed nasopharyngeal carcinoma

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: capecitabinemetastatic nasopharyngeal carcinomanasopharyngeal carcinoma
Previous Post

Video game interventions may improve depressive symptoms in adolescents and young adults

Next Post

Abemaciclib linked to disease control in patients with p16ink4A-negative mesothelioma

RelatedReports

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
StudyGraphics

#VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma

May 19, 2022
#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
StudyGraphics

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

May 18, 2022
#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in  premenopausal women with ER+ breast cancer and ovarian suppression
StudyGraphics

#VisualAbstract: Upper neck irradiation is noninferior to whole neck irradiation for newly diagnosed nasopharyngeal carcinoma

May 4, 2022
Patient Basics: Nosebleed (Epistaxis)
Oncology

Induction chemotherapy with paclitaxel, cisplatin and capecitabine showed promising clinical and safety response to treat advanced nasopharyngeal carcinoma

April 4, 2022
Next Post
Dacomitinib may be effective in EGFR-associated lung cancer

Abemaciclib linked to disease control in patients with p16ink4A-negative mesothelioma

Stem cell transplant may be effective in sickle cell disease

LentiGlobin efficacious for sickle cell disease hemolysis and vaso-occlusion

Cervical cancer screening practices less cost-effective than suggested guidelines

Sintilimab plus anlotinib showed promising clinical and safety response to treat advanced cervical cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
  • Operating the day after performing surgery the previous night not associated with adverse patient outcomes
  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.